Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins.
Biochemistry & Molecular Pharmacology
Graduate School of Biomedical Sciences, Cancer Biology Program; Program in Gene Function and Expression; Program in Molecular Medicine
Cancer Biology | Life Sciences | Medicine and Health Sciences
Hematologic malignancies are typically associated with leukemogenic fusion proteins, which are required to maintain the oncogenic state. Previous studies have shown that certain oncogenes that promote solid tumors, such as RAS and BRAF, can induce senescence in primary cells, which is thought to provide a barrier to tumorigenesis. In these cases, the activated oncogene elicits a DNA damage response (DDR), which is essential for the senescence program. Here we show that 3 leukemogenic fusion proteins, BCR-ABL, CBFB-MYH11, and RUNX1-ETO, can induce senescence in primary fibroblasts and hematopoietic progenitors. Unexpectedly, we find that senescence induction by BCR-ABL and CBFB-MYH11 occurs through a DDR-independent pathway, whereas RUNX1-ETO induces senescence in a DDR-dependent manner. All 3 fusion proteins activate the p38 MAPK pathway, which is required for senescence induction. Our results reveal diverse pathways for oncogene-induced senescence and further suggest that leukemias harbor genetic or epigenetic alterations that inactivate senescence induction genes.
DOI of Published Version
Blood. 2010 Jun 17;115(24):5057-60. Epub 2010 Apr 26.
Wajapeyee N, Wang S, Serra RW, Solomon PD, Nagarajan A, Zhu X, Green MR. (2010). Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins.. GSBS Student Publications. https://doi.org/10.1182/blood-2009-09-245928. Retrieved from https://escholarship.umassmed.edu/gsbs_sp/1649